Clinical Trial

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-01-26; most recent amendment 2026-05-03.
Status change: Not Yet Recruiting → Recruiting 2024-06-12
Trial Details
NCT Number NCT06239194
Lead Sponsor ModeX Therapeutics, An OPKO Health Company
Conditions Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer +8 more
Enrollment 285 participants
Start Date 2024-06-12
Primary Completion 2028-08 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-06